222 related articles for article (PubMed ID: 38483699)
1. The role of the BTLA-HVEM complex in the pathogenesis of breast cancer.
Hu X
Breast Cancer; 2024 May; 31(3):358-370. PubMed ID: 38483699
[TBL] [Abstract][Full Text] [Related]
2. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
3. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
[TBL] [Abstract][Full Text] [Related]
5. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
[TBL] [Abstract][Full Text] [Related]
6. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
[TBL] [Abstract][Full Text] [Related]
7. Role of BTLA/HVEM network in development of gastric cancer.
Azarafza M; Tehrani M; Valadan R; Maleki I; Mohammad Mehdi Ghaffari-Hamedani S; Ghanadan A; Alizadeh-Navaei R; Ajami A
Hum Immunol; 2022; 83(8-9):637-644. PubMed ID: 35914980
[TBL] [Abstract][Full Text] [Related]
8. The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.
Shang Y; Guo G; Cui Q; Li J; Ruan Z; Chen Y
Inflammation; 2012 Jun; 35(3):1102-12. PubMed ID: 22179929
[TBL] [Abstract][Full Text] [Related]
9. Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Rodziewicz-Motowidło S; Wardowska A; Spodzieja M
Biomed Pharmacother; 2024 Jun; 175():116675. PubMed ID: 38733770
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
11. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
12. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
13. BTLA inhibition has a dominant role in the
Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
Front Immunol; 2022; 13():956694. PubMed ID: 36081508
[TBL] [Abstract][Full Text] [Related]
14. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
15. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
16. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.
Sakoda Y; Park JJ; Zhao Y; Kuramasu A; Geng D; Liu Y; Davila E; Tamada K
Blood; 2011 Feb; 117(8):2506-14. PubMed ID: 21220749
[TBL] [Abstract][Full Text] [Related]
17. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of BTLA and HVEM Expression on Circulating CD4
Song HF; Chen XJ; Tang PJ; Xu P; Huang ZY; Wang XF
Viral Immunol; 2022 May; 35(4):291-302. PubMed ID: 35196150
[TBL] [Abstract][Full Text] [Related]
19. The BTLA-HVEM complex - The future of cancer immunotherapy.
Wojciechowicz K; Spodzieja M; Wardowska A
Eur J Med Chem; 2024 Mar; 268():116231. PubMed ID: 38387336
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
